Beximco exports third item `Methocarbamol` to US market

Dhaka, Wednesday   08 April 2020


Beximco exports third item `Methocarbamol` to US market

 News Desk Daily-Bangladesh

 Published: 08:06 PM, 24 April 2018  



Prominent pharmaceutical company `Beximco Pharmaceuticals` has started the export of its third item `Methocarbamol` (500mg and 700mg) to the United States. 

After the successful marketing of Carvedilol and Sotalol in August 2016 and November 2017, `Beximco Pharmaceuticals` becomes the first consignment to export its third item delivered on this April 21, said a press release today

According to IQVIA market data, `Methocarbamol` is generic equivalent to muscle relaxant drug Robaxin from Auxilium Pharmaceuticals, the US market for Methocarbamol is currently valued at USD 23.37 million. 

Beximco Pharma managing director Nazmul Hassan, MP, said we will continue to focus on growing our market in the US, which we believe will be a major export market for Beximco Pharma in the coming years.

Nazmul Hassan also said we will remain focused on our strategic goal to bring high quality, differentiated products to both developed and key emerging markets to create value for our customers and shareholders.

Beximco Pharma is the only Bangladeshi pharmaceutical company to export medicine to the US market following its manufacturing site approval by the US Food and Drug Administration in June 2015.

Currently, `Beximco Pharmaceuticals` has a global footprint in more than 50 countries and has been accredited by the leading global regulatory authorities namely US FDA, AGES (EU), TGA (Australia), Health Canada, GCC (Gulf) and TFDA (Taiwan).